🔎 Trials Near Me

Beranda › Tumor Otak › Pennsylvania

Uji klinis Tumor Otak di Pennsylvania

13 studi untuk Tumor Otak mencari peserta di lokasi di Pennsylvania.

Kota di Pennsylvania

Teks studi resmi (Bahasa Inggris)

Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII

  • Thomas Jefferson University, Sidney Kimmel Comprehensive Cancer Center, Philadelphia
  • UPMC Hillman Cancer Center, Pittsburgh
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT07326566

A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases

  • University of Pittsburgh Cancer Institute (UPCI), Pittsburgh
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 15 Sep 2026 · NCT04511013

Targeted Pediatric High-Grade Glioma Therapy

  • Children's Hospital of Philadelphia, Philadelphia
Menerima pesertaStudi observasional
12 Months – 39 Years · Semua jenis kelamin · Diperbarui 8 Sep 2026 · NCT05839379

Study of Olutasidenib and Temozolomide in HGG

  • Children's Hospital of Philadelphia, Philadelphia
Menerima pesertaFase 2
Usia 12 hingga 39 · Semua jenis kelamin · Diperbarui 1 Sep 2026 · NCT06161974

WBSI Guided Personalized Delivery of TTFields

  • Abramson Cancer Center, Philadelphia
  • Penn Medicine, University of Pennsylvania, Philadelphia
Menerima peserta
Usia 22 ke atas · Semua jenis kelamin · Diperbarui 6 Agu 2026 · NCT05086497

Illuminate: A Clinical Study Evaluating CAR T Immune Cell Therapy (BCB-276) for Patients With Diffuse Intrinsic Pontine Glioma (DIPG).

  • Children's Hospital of Philadelphia, Philadelphia
Menerima pesertaFase 2
Usia 1 hingga 26 · Semua jenis kelamin · Diperbarui 4 Agu 2026 · NCT07680439

Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles)

  • St Luke's University Health, Sacred Heart Campus, Allentown
  • Penn State Health, Hershey
  • Allegheny Health Network, Pittsburgh
Menerima pesertaStudi observasional
Semua usia · Semua jenis kelamin · Diperbarui 22 Jul 2026 · NCT04427384

Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or More Brain Metastases

  • Geisinger Medical Center, Danville
  • Geisinger Wyoming Valley/Henry Cancer Center, Wilkes-Barre
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 9 Jun 2026 · NCT03550391

Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant

  • Children's Hospital of Philadelphia, Philadelphia
Menerima pesertaFase 2
12 Months – 39 Years · Semua jenis kelamin · Diperbarui 29 Mei 2026 · NCT05843253

Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery

  • Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia
Menerima peserta
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Mei 2026 · NCT03184038

The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study

  • Allegheny Health Network, Pittsburgh
Menerima pesertaStudi observasional
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 5 Mar 2026 · NCT04075305

S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity

  • Lehigh Valley Hospital-Cedar Crest, Allentown
  • Lehigh Valley Hospital - Muhlenberg, Bethlehem
  • Penn State Milton S Hershey Medical Center, Hershey
  • dan 1 lainnya
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 8 Okt 2025 · NCT03418961

APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors

  • Penn State Milton S. Hershey Medical Center, Hershey
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 27 Jun 2025 · NCT03175224

Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.